Pluripotency and nuclear reprogramming.
Embryonic stem cells are promising donor cell sources for cell transplantation therapy, which may in the future be used to treat various diseases and injuries. However, as is the case for organ transplantation, immune rejection after transplantation is a potential problem with this type of therapy. Moreover, the use of human embryos presents serious ethical difficulties. These issues may be overcome if pluripotent stem cells are generated from patients' somatic cells. Here, we review the molecular mechanisms underlying pluripotency and the currently known methods of inducing pluripotency in somatic cells.
Yamanaka
Shinya
S
Center for iPS Cell Research & Application, Kyoto University, Kyoto 606-8507, Japan. yamanaka@frontier.kyoto-u.ac.jp
D002454:Cell Differentiation / Q000502:physiology*; D065150:Cellular Reprogramming; D005786:Gene Expression Regulation / Q000235:genetics / Q000502:physiology*; D006801:Humans; D053652:Nuclear Transfer Techniques; D039904:Pluripotent Stem Cells / Q000166:cytology*; D033581:Stem Cell Transplantation / Q000379:methods*; D014157:Transcription Factors / Q000235:genetics / Q000502:physiology*
D014157:Transcription Factors